TELA vs. ARAY, CLPT, CVRX, QIPT, KRMD, DRTS, OBIO, ALUR, BLUA, and BWAY
Should you be buying TELA Bio stock or one of its competitors? The main competitors of TELA Bio include Accuray (ARAY), ClearPoint Neuro (CLPT), CVRx (CVRX), Quipt Home Medical (QIPT), KORU Medical Systems (KRMD), Alpha Tau Medical (DRTS), Orchestra BioMed (OBIO), Allurion Technologies (ALUR), BlueRiver Acquisition (BLUA), and BrainsWay (BWAY). These companies are all part of the "surgical & medical instruments" industry.
Accuray (NASDAQ:ARAY) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Accuray has higher revenue and earnings than TELA Bio. Accuray is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
Accuray received 279 more outperform votes than TELA Bio when rated by MarketBeat users. However, 72.22% of users gave TELA Bio an outperform vote while only 65.67% of users gave Accuray an outperform vote.
In the previous week, TELA Bio had 16 more articles in the media than Accuray. MarketBeat recorded 17 mentions for TELA Bio and 1 mentions for Accuray. TELA Bio's average media sentiment score of 1.26 beat Accuray's score of 0.48 indicating that Accuray is being referred to more favorably in the media.
Accuray has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Accuray presently has a consensus price target of $8.25, suggesting a potential upside of 394.01%. TELA Bio has a consensus price target of $13.00, suggesting a potential upside of 104.40%. Given TELA Bio's higher possible upside, research analysts plainly believe Accuray is more favorable than TELA Bio.
Accuray has a net margin of -4.99% compared to Accuray's net margin of -63.82%. TELA Bio's return on equity of -44.46% beat Accuray's return on equity.
64.1% of Accuray shares are held by institutional investors. Comparatively, 94.3% of TELA Bio shares are held by institutional investors. 3.8% of Accuray shares are held by insiders. Comparatively, 6.0% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Accuray beats TELA Bio on 10 of the 16 factors compared between the two stocks.
Get TELA Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TELA Bio Competitors List
Related Companies and Tools
